Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

Fig. 2

Observed individual-level VRC07-523LS serum concentrations over time. Colors represent different dose levels of VRC07-523LS at 2.5, 5 or 20 mg/kg; shapes represent route of administration via subcutaneous or intravenous; filled vs. open symbols represent combination vs. single administrations, respectively. Each line in the graph indicates a unique participant. Figure S2 shows observed individual-level VRC07-523LS serum concentrations over time delineated by intravenous and subcutaneous SPA. Figure S3 shows observed individual-level VRC07-523LS serum concentrations over time delineated by combination and single SPA. Abbreviations: IV- intravenous; SC- subcutaneous; SPA: study product administration

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us